0SGC Stock Overview
A biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Arbutus Biopharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.48 |
| 52 Week High | US$4.68 |
| 52 Week Low | US$1.81 |
| Beta | 1.92 |
| 11 Month Change | -14.43% |
| 3 Month Change | -10.55% |
| 1 Year Change | 92.07% |
| 33 Year Change | 9.45% |
| 5 Year Change | n/a |
| Change since IPO | -4.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0SGC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.3% | 0.3% | 2.2% |
| 1Y | 92.1% | -18.3% | 8.0% |
Return vs Industry: 0SGC exceeded the UK Biotechs industry which returned -18.3% over the past year.
Return vs Market: 0SGC exceeded the UK Market which returned 8% over the past year.
Price Volatility
| 0SGC volatility | |
|---|---|
| 0SGC Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0SGC has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0SGC's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 73 | Mike McElhaugh | www.arbutusbio.com |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
Arbutus Biopharma Corporation Fundamentals Summary
| 0SGC fundamental statistics | |
|---|---|
| Market cap | US$665.12m |
| Earnings (TTM) | -US$76.70m |
| Revenue (TTM) | US$6.74m |
98.7x
P/S Ratio-8.7x
P/E RatioIs 0SGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0SGC income statement (TTM) | |
|---|---|
| Revenue | US$6.74m |
| Cost of Revenue | US$62.79m |
| Gross Profit | -US$56.05m |
| Other Expenses | US$20.65m |
| Earnings | -US$76.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -831.34% |
| Net Profit Margin | -1,137.64% |
| Debt/Equity Ratio | 5.0% |
How did 0SGC perform over the long term?
See historical performance and comparison